Cat. No.: HY-10519

BMS-345541

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC₅₀=0.3 μM, IKK-1 IC₅₀=4 μM). BMS-345541 binds at an allosteric site of IKK.

For research use only. We do not sell to patients.

Purity: 99.79%
CAS No.: 445430-58-0
Formula: C₁₄H₁₇N₅
Molecular Weight:255.32

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BMS-345541 Chemical Structure

CAS No.: 445430-58-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC₅₀=0.3 μM, IKK-1 IC₅₀=4 μM). BMS-345541 binds at an allosteric site of IKK.

IC₅₀ & Target^[1]

IKK-2

0.3 μM (IC₅₀)

IKK-1

4 μM (IC₅₀)

All IKK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.6 μM Compound: BMS345541	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
A549	IC₅₀	8.6 μM Compound: BMS345541	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
Jurkat	CC₅₀	100 μM Compound: 1	Cytotoxicity against Jurkat cells by Alamar blue assay Cytotoxicity against Jurkat cells by Alamar blue assay	[PMID: 17540562]
Jurkat	EC₅₀	13.3 μM Compound: 1	Inhibition of LPS-induced TNFalpha production in Jurkat cells Inhibition of LPS-induced TNFalpha production in Jurkat cells	[PMID: 17540562]
L02	IC₅₀	15.3 μM Compound: BMS345541	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
Lewis lung carcinoma cell line	IC₅₀	4.8 μM Compound: BMS345541	Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay	[PMID: 27886548]
NCI-H1650	IC₅₀	19.9 μM Compound: BMS345541	Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
NCI-H1650	IC₅₀	9.3 μM Compound: BMS345541	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H1975	IC₅₀	8 μM Compound: BMS345541	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	IC₅₀	2.8 μM Compound: BMS345541	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
PBMC	EC₅₀	0.8 μM Compound: 1	Inhibition of LPS-induced TNFalpha production in PBMC Inhibition of LPS-induced TNFalpha production in PBMC	[PMID: 17540562]
PBMC	IC₅₀	1 μM Compound: 1, BMS-345541	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha release treated for 5 mins before LPS challenge measured after 6 hrs by ELISA Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha release treated for 5 mins before LPS challenge measured after 6 hrs by ELISA	[PMID: 21087862]
THP-1	IC₅₀	1 μM Compound: Chemical probe : BMS-345541	Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-1beta cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-1beta cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay	[PMID: 12403772]
THP-1	IC₅₀	1 μM Compound: Chemical probe : BMS-345541	Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-6 cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 24 hrs by enzyme immunoassay Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-6 cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 24 hrs by enzyme immunoassay	[PMID: 12403772]
THP-1	IC₅₀	1 μM Compound: Chemical probe : BMS-345541	Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-8 cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in IL-8 cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay	[PMID: 12403772]
THP-1	IC₅₀	1 μM Compound: Chemical probe : BMS-345541	Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in TNFalpha cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay Antiinflammatory activity against LPS-induced human THP-1 cells assessed as reduction in TNFalpha cytokine level preincubated for 1 hr followed by LPS-stimulation and measured after 6 hrs by enzyme immunoassay	[PMID: 12403772]

In Vitro

BMS-345541 selectively inhibits the stimulated phosphorylation of IκBα in cells (IC₅₀=4 μM). Consistent with the role of IKK/NF-κB in the regulation of cytokine transcription, BMS-345541 inhibits lipopolysaccharide-stimulated tumor necrosis factor α, interleukin-1β, interleukin-8, and interleukin-6 in THP-1 cells with IC₅₀ values in the 1 to 5 μM range^[1]. BMS-345541 treatment results in a concentration-dependent inhibition of melanoma cell proliferation in SK-MEL-5, A375, and Hs 294T cells. BMS-345541 (0, 100 μM) shows apoptotic features as revealed by TUNEL staining and nuclear condensation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-345541 (10 mg/kg, p.o.) results in prolonged serum drug levels, with concentrations sustained at or above 1 μM for many hours in mice. BMS-345541 dose-dependently inhibits the production of TNFα measured in the serum of animals challenged with an intraperitoneal administration of LPS^[1]. BMS-345541 (0, 10, 25, and 75 mg/kg, p.o.) effectively inhibits SK-MEL-5 tumor growth in a dose-dependent manner in the mice. Tumor-bearing mice treated with 75 mg/kg of BMS-345541 show effective inhibition of growth of SK-MEL-5, A375, and Hs 294T tumors by 86±2.8%, 69±11% and 67±3.4%, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 445430-58-0
Appearance Solid
Molecular Weight 255.32
Formula C₁₄H₁₇N₅
Color White to off-white
SMILES

CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (38)

All WBCell Migration/Invasion AssayFlow CytometryCell Proliferation/Viability AssayIFRT-PCR

Sort by:

Journal Impact Factor

Cancer Cell

Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. [Abstract]

2015 Mar 9;27(3):409-25. PMID: 25759025

BMS-345541 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2015 Mar 9;27(3):409-25. [Abstract]

pre-BCR⁺ ALL cells, pre-BCR^- ALL cells and mature B cell lymphoma cells were treated with BMS-345541 hydrochloride (1-64 μM) and cell viability was measured by CCK-8 at different dose levels.
Cell Res

Virus-induced accumulation of intracellular bile acids activates the TGR5-β-arrestin-SRC axis to enable innate antiviral immunity. [Abstract]

2019 Mar;29(3):193-205. PMID: 30651583
Nat Metab

Thermogenic adipocyte-derived zinc promotes sympathetic innervation in male mice. [Abstract]

2023 Mar;5(3):481-494. PMID: 36879120

BMS-345541 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2023 Mar;5(3):481-494. [Abstract]

Mt2gene expression in beige adipocytes treated with indicated compounds (50 ng/mL TNF, 2 μM BMS345541, 1 μM SCH772984, 5 μM SB202190 and 5 μM SP600125; n = 4 biological independent samples).
Sci Transl Med

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. [Abstract]

2021 Jan 27;13(578):eaba7308. PMID: 33504651
Interdiscip Med

2026 May 18.
Mol Biomed

Death-associated protein kinase 2 (DAPK2) propagates endoplasmic reticulum stress in macrophages to worsen sepsis through HSPA5-IRE1α axis. [Abstract]

2026 Jun 23;7(1):94. PMID: 42334722
J Immunother Cancer

Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer. [Abstract]

2026 Jun 3;14(6):e014253. PMID: 42236112
Phytomedicine

Complementary roles and synergy of the Ephedra-Glycyrrhiza herb pair across murine models of respiratory symptoms and poly(I:C)-induced pneumonia. [Abstract]

2026 Feb:151:157795. PMID: 41539102
Am J Hematol

miR-146a-/- mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype. [Abstract]

2024 Jul;99(7):1326-1337. PMID: 38646919
J Hazard Mater Adv

2026 Mar 7.
Int J Biol Macromol

Lipocalin 2 deficiency attenuates NLRP3 inflammasome activation through glycolysis impairment and MGST1-mediated mitochondrial ROS reduction. [Abstract]

2025 Dec;334(Pt 1):149021. PMID: 41260431
EMBO Mol Med

Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]

2025 Nov 26. PMID: 41299101
EMBO Mol Med

Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. [Abstract]

2025 Apr;17(4):645-678. PMID: 39972068
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
J Dent Res

Macrophages Promote Growth of Squamous Cancer Independent of T cells. [Abstract]

2019 Jul;98(8):896-903. PMID: 31189369

BMS-345541 purchased from MedChemExpress. Usage Cited in: J Dent Res. 2019 Jul;98(8):896-903. [Abstract]

A223 and FaDu cells were treated with 5 µM BMS345541 for 18 h, and wb was detected.
Cancer Metab

Subclinical dose irradiation triggers human breast cancer migration via mitochondrial reactive oxygen species. [Abstract]

2024 Jul 8;12(1):20. PMID: 38978126

BMS-345541 purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2024 Jul 8;12(1):20. [Abstract]

The migratory activity of MCF7 or MDA-MB-231 cells was assessed 24 h after treatment ± NF-κB inhibitor BMS-345541 (10 µM).
Front Microbiol

Cellular CARD11 Inhibits the Fusogenic Activity of Newcastle Disease Virus via CBM Signalosome-Mediated Furin Reduction in Chicken Fibroblasts. [Abstract]

2021 Feb 2;12:607451. PMID: 33603723

BMS-345541 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 Feb 2;12:607451. [Abstract]

BAY 11-7082, BMS-345541 (0.1-10 μM), and MI-2 at different concentrations for 24 h. These cells were observed and harvested to detect cell survival using flow cytometry. Scale bar = 50 μm.
Int Immunopharmacol

Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K/Akt pathway. [Abstract]

2021 Dec;101(Pt A):108264. PMID: 34715493
Molecules

Investigating Natural Product Inhibitors of IKKα: Insights from Integrative In Silico and Experimental Validation. [Abstract]

2025 May 2;30(9):2025. PMID: 40363830
J Mol Med

Chemically modified curcumin (CMC2.24) alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis. [Abstract]

2020 Oct;98(10):1479-1491. PMID: 32860098

BMS-345541 purchased from MedChemExpress. Usage Cited in: J Mol Med. 2020 Oct;98(10):1479-1491. [Abstract]

BMS-345541 (5 μM; 2 h) greatly enhanced CMC2.24-mediated decrease in the translocation of p65 subunits to the nuclei of chondrocytes.

BMS-345541 purchased from MedChemExpress. Usage Cited in: J Mol Med. 2020 Oct;98(10):1479-1491. [Abstract]

BMS-345541 (5 μM) remarkably enhanced CMC2.24-mediated decrease in MMP-3, cleaved caspase-3, VEGF, RUNX2, p-p65, p-IκB-α, and Hif-2α expression, and increase in Col2a1 and Bcl-2 expression in chondrocytes.
Cancer Sci

NF-κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma. [Abstract]

2025 Nov 14. PMID: 41236113
PLoS Pathog

Influenza virus infection reprograms cholesterol biosynthesis to facilitate virus replication by the TAK1-RORγ axis. [Abstract]

2025 Oct 24;21(10):e1013646. PMID: 41134862

BMS-345541 purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2025 Oct 24;21(10):e1013646. [Abstract]

NL20 cells were infected with 0.1 MOI of H5N1 (SY) virus and then treated with the indicated concentrations of the JNK inhibitor (SP600125, SP), the IKK inhibitor (BMS345541, BMS, 0-10 μM) and the TAK1 inhibitor (5Z-oxzeneonal, 5Z) for 24 h. Cell lysates were prepared and analyzed for the levels of the PB2 and NP proteins by Western blots. GAPDH was detected as a loading control.
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
Antiviral Res

Porcine epidemic diarrhea virus infection activates SREBP2 and induces RORγ expression to enhance cholesterol biosynthesis and virus replication. [Abstract]

2026 May:249:106391. PMID: 41796918
Am J Physiol Endocrinol Metab

1,25-Dihydroxyvitamin D deficiency accelerates male reproductive senescence in aging mice and 1,25(OH)2D3 alleviates oxidative stress via NF-κB/SOD. [Abstract]

2021 Apr 1;320(4):E732-E746. PMID: 33586492
J Virol

Host CARD11 Inhibits Newcastle Disease Virus Replication by Suppressing Viral Polymerase Activity in Neurons. [Abstract]

2019 Nov 26;93(24):e01499-19. PMID: 31554683
PLoS Comput Biol

A systematic approach to decipher crosstalk in the p53 signaling pathway using single cell dynamics. [Abstract]

2020 Jun 26;16(6):e1007901. PMID: 32589666
J Pharmacol Sci

Regulatory action of PGRMC1 on cyclic AMP-mediated COX2 expression in human endometrial cells. [Abstract]

2023 Dec;153(4):188-196. PMID: 37973216
Biochem Biophys Res Commun

Engrailed 2 triggers the activation of multiple phosphorylation-induced signaling pathways in both transcription-dependent and -independent manners. [Abstract]

2023 Nov 5:680:127-134. PMID: 37738902
J Vet Sci

Subcutaneous Streptococcus dysgalactiae GAPDH vaccine in mice induces a proficient innate immune response. [Abstract]

2023 Sep;24(5):e72. PMID: 38031651
Photobiomodul Photomed Laser Surg

Photobiomodulation Promotes Odontoblast-Like Cell Activity via Reactive Oxygen Species and NF-κB: Implications for Dentin Regeneration. [Abstract]

2025 Jul 24. PMID: 40711932
University of Pittsburgh

2026.
bioRxiv

CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins. [Abstract]

2026 Apr 22:2026.04.19.719504. PMID: 42079201
bioRxiv

2025 Oct 25.
bioRxiv

In vivo CRISPR screening links NFKB1 to endocrine resistance in ER⁺ breast cancer. [Abstract]

2025 Aug 13:2025.08.11.669793. PMID: 40832193
Research Square Print

October 27th, 2022.
Aging (Albany NY)

Senescence-associated hyper-activation to inflammatory stimuli in vitro. [Abstract]

2021 Aug 10;13(15):19088-19107. PMID: 34375950
Biomed Pharmacother

Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. [Abstract]

2020 Jul;127:110116. PMID: 32428833

BMS-345541 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Jul;127:110116. [Abstract]

Relative NFκB, p-NFκB, p-IKBα and t-IKBα protein levels in spheres in the control, TNFα, TNFα + BMS-345541 and TNFα + resveratrol groups.

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (39.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2.5 mg/mL (9.79 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9167 mL

19.5833 mL

39.1665 mL

5 mM

0.7833 mL

3.9167 mL

7.8333 mL

10 mM

0.3917 mL

1.9583 mL

3.9167 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

Assays measuring the enzyme-catalyzed phosphorylation of GST-IκBα are performed by adding enzyme (IKK-2, IKK-1, or IKK-ε, typically to a final concentration of 0.5 μg/mL) at 30°C to solutions of 100 μg/mL GST-IκBα and 5 μM [³³P]ATP in 40 mM Tris-HCl, pH 7.5, containing 4 mM MgCl₂, 34 mM sodium phosphate, 3 mM NaCl, 0.6 mM potassium phosphate, 1 mM KCl, 1 mM dithiothreitol, 3% (w/v) glycerol, and 250 μg/mL bovine serum albumin. The specific activity of [³³P]ATP used in the assay is 100 Ci/mmol. After 5 min, the kinase reactions are stopped by the addition of 2× LaemmLi sample buffer and heat-treated at 90°C for 1 min. The samples are then loaded on to NuPAGE 10% BisTris gels. After completion of SDS-PAGE, gels are dried on a slab gel dryer. The bands are then detected using a 445Si PhosphorImager, and the radioactivity is quantified using ImageQuant software. Under these conditions, the degree of phosphorylation of GST-IκBα is linear with time and concentration of enzyme^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

SK-MEL-5 cells are treated with BMS-345541 at different concentrations (0, 1.0, 10, and 100 μM) for different time periods. The cells are collected by trypsinization, fixed in 70% ethanol for 2 hours on ice and stained with PI solution (PBS containing 2 μg/mL PI, 0.1% Triton X-100, and 125 units/mL RNase A) at 37°C for 30 minutes. Cell fluorescence is measured by flow cytometry with 488 nm excitation and 620 nm emission filters and resulting data are analyzed using the software program MultiCycle^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
BMS-345541 is administered either by intravenous tail vein injection or by peroral gavage to groups of three 18-22 g female BALB/c mice. BMS-345541 is formulated as a 2 mg/mL solution in 3% Tween 80, water. Mice receive either a 2 mg/kg (1 mL/kg) intravenous bolus or a 10 mg/kg (5 mL/kg) peroral gavage. Whole blood samples are taken from individual mice by orbital bleed and cardiac puncture at 0, 0.05, 0.25, 0.5, 1.0, 3.0, 6.0, and 8.0 h after dosing. Whole blood is centrifuged at 20×10³×g for 5 min. Serum is stored at -20°C until analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3), 1450-1456. [Content Brief]

[2]. Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12(3 Pt 1), 950-960. [Content Brief]

[3]. MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52(12), 508-511. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.9167 mL	19.5833 mL	39.1665 mL	97.9163 mL
H₂O / DMSO	5 mM	0.7833 mL	3.9167 mL	7.8333 mL	19.5833 mL
DMSO	10 mM	0.3917 mL	1.9583 mL	3.9167 mL	9.7916 mL
	15 mM	0.2611 mL	1.3056 mL	2.6111 mL	6.5278 mL
	20 mM	0.1958 mL	0.9792 mL	1.9583 mL	4.8958 mL
	25 mM	0.1567 mL	0.7833 mL	1.5667 mL	3.9167 mL
	30 mM	0.1306 mL	0.6528 mL	1.3056 mL	3.2639 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

BMS-345541

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-345541

All IKK Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BMS-345541

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-345541

All IKK Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BMS-345541 Related Classifications

HY-10519 Related Classifications